Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody
Authors:
Open Access
- 25 September 2015
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 279 (1) , 41-59
Abstract
The introduction of targeted biological therapies has revolutionised the management of immune‐mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease. Following treatment with these therapies, many patients experience significant improvements in different aspects of their disease, including symptoms, work productivity and other outcomes relevant for individuals and society. However, due to the complexity of biological drug development and manufacturing processes, the costs of these therapies are relatively high. Indeed, the financial burden on healthcare systems due to biological therapies is considerable and lack of patient access to effective treatment remains a concern in many parts of the world. As many reference biological therapies have now reached or are near to patent expiry, a number of ‘biosimilar’ drugs have been developed for use in various clinical settings, and some of these drugs are already in use in several countries. While the potential pharmacoeconomic benefits of cost‐effective biosimilars seem clear, several issues have been raised regarding, for example, the definition of biosimilarity and the validity of indication extrapolation, as well as the ‘switchability’ and relative immunogenicity of biosimilars and their reference drugs. In this review, these issues will be discussed with reference to CT‐P13, a biosimilar of the anti‐tumour necrosis factor monoclonal antibody infliximab, which is approved in Europe and elsewhere for the treatment of various IMIDs. Other important issues, including those related to data collection during nonclinical and clinical development of biosimilars, are also discussed.Keywords
Funding Information
- Abbott Laboratories
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis
- Pfizer
- Roche
This publication has 54 references indexed in Scilit:
- Einführung und Gebrauch von „biosimilars“ in der Therapie entzündlich-rheumatischer ErkrankungenZeitschrift für Rheumatologie, 2014
- The challenge of indication extrapolation for infliximab biosimilarsBiologicals, 2014
- The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritisExpert Review of Clinical Immunology, 2014
- Biosimilars: In support of extrapolation of indicationsJournal of Crohn's and Colitis, 2014
- Inequities in access to biologic and synthetic DMARDs across 46 European countriesAnnals of the Rheumatic Diseases, 2014
- Developing Oncology Biosimilars: An Essential Approach for the FutureSeminars in Oncology, 2013
- Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesAlimentary Pharmacology & Therapeutics, 2013
- Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional studyArchives of Dermatological Research, 2013
- Biosimilar Insulins: How Similar is Similar?Journal of Diabetes Science and Technology, 2011
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007